vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and John Marshall Bancorp, Inc. (JMSB). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $16.8M, roughly 1.1× John Marshall Bancorp, Inc.). John Marshall Bancorp, Inc. runs the higher net margin — 36.3% vs -0.8%, a 37.2% gap on every dollar of revenue. Over the past eight quarters, John Marshall Bancorp, Inc.'s revenue compounded faster (15.3% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.
CTMX vs JMSB — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $16.8M |
| Net Profit | $-154.0K | $6.1M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | — |
| Net Margin | -0.8% | 36.3% |
| Revenue YoY | -25.7% | — |
| Net Profit YoY | 97.6% | 26.8% |
| EPS (diluted) | — | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $16.8M | ||
| Q4 25 | — | $16.4M | ||
| Q3 25 | — | $16.3M | ||
| Q2 25 | $18.7M | $15.4M | ||
| Q1 25 | $50.9M | $14.6M | ||
| Q4 24 | $38.1M | $14.3M | ||
| Q3 24 | $33.4M | $13.8M | ||
| Q2 24 | $25.1M | $12.6M |
| Q1 26 | — | $6.1M | ||
| Q4 25 | — | $5.9M | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | $-154.0K | $5.1M | ||
| Q1 25 | $23.5M | $4.8M | ||
| Q4 24 | $18.9M | $4.8M | ||
| Q3 24 | $5.7M | $4.2M | ||
| Q2 24 | $-6.5M | $3.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 47.4% | ||
| Q3 25 | — | 42.2% | ||
| Q2 25 | -6.9% | 42.7% | ||
| Q1 25 | 44.4% | 42.4% | ||
| Q4 24 | 46.4% | 42.5% | ||
| Q3 24 | 12.3% | 38.8% | ||
| Q2 24 | -33.7% | 39.7% |
| Q1 26 | — | 36.3% | ||
| Q4 25 | — | 36.2% | ||
| Q3 25 | — | 33.2% | ||
| Q2 25 | -0.8% | 33.1% | ||
| Q1 25 | 46.2% | 32.9% | ||
| Q4 24 | 49.6% | 33.3% | ||
| Q3 24 | 17.2% | 30.7% | ||
| Q2 24 | -26.0% | 30.9% |
| Q1 26 | — | $0.43 | ||
| Q4 25 | — | $0.41 | ||
| Q3 25 | — | $0.38 | ||
| Q2 25 | — | $0.36 | ||
| Q1 25 | — | $0.34 | ||
| Q4 24 | — | $0.33 | ||
| Q3 24 | — | $0.30 | ||
| Q2 24 | — | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $150.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $268.1M |
| Total Assets | $175.1M | $2.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $150.2M | ||
| Q4 25 | — | $130.0M | ||
| Q3 25 | — | $163.6M | ||
| Q2 25 | $49.0M | $116.9M | ||
| Q1 25 | $47.6M | $169.1M | ||
| Q4 24 | $38.1M | $122.5M | ||
| Q3 24 | $40.6M | $177.2M | ||
| Q2 24 | $43.2M | $182.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $80.9M | ||
| Q3 25 | — | $80.9M | ||
| Q2 25 | — | $80.8M | ||
| Q1 25 | — | $80.8M | ||
| Q4 24 | — | $80.8M | ||
| Q3 24 | — | $80.8M | ||
| Q2 24 | — | $24.7M |
| Q1 26 | — | $268.1M | ||
| Q4 25 | — | $265.6M | ||
| Q3 25 | — | $259.7M | ||
| Q2 25 | $119.9M | $253.7M | ||
| Q1 25 | $25.0M | $253.0M | ||
| Q4 24 | $-456.0K | $246.6M | ||
| Q3 24 | $-23.5M | $243.1M | ||
| Q2 24 | $-31.2M | $235.3M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | $175.1M | $2.3B | ||
| Q1 25 | $98.5M | $2.3B | ||
| Q4 24 | $120.5M | $2.2B | ||
| Q3 24 | $139.0M | $2.3B | ||
| Q2 24 | $159.2M | $2.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 0.32× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.33× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | — |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $22.6M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | $-15.8M | $7.5M | ||
| Q1 25 | $-21.0M | $7.0M | ||
| Q4 24 | $-19.9M | $17.3M | ||
| Q3 24 | $-20.7M | $1.4M | ||
| Q2 24 | $-19.5M | $10.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $22.0M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | $-15.8M | $7.4M | ||
| Q1 25 | $-21.2M | $6.6M | ||
| Q4 24 | $-20.0M | $16.8M | ||
| Q3 24 | $-20.7M | $1.3M | ||
| Q2 24 | $-19.6M | $10.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 134.7% | ||
| Q3 25 | — | 7.3% | ||
| Q2 25 | -84.6% | 47.8% | ||
| Q1 25 | -41.6% | 45.3% | ||
| Q4 24 | -52.5% | 116.9% | ||
| Q3 24 | -62.1% | 9.5% | ||
| Q2 24 | -78.2% | 80.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | 0.1% | 1.0% | ||
| Q1 25 | 0.2% | 2.3% | ||
| Q4 24 | 0.2% | 3.4% | ||
| Q3 24 | 0.1% | 0.8% | ||
| Q2 24 | 0.4% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.82× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 1.48× | ||
| Q1 25 | -0.89× | 1.45× | ||
| Q4 24 | -1.05× | 3.61× | ||
| Q3 24 | -3.61× | 0.33× | ||
| Q2 24 | — | 2.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
JMSB
| Net Interest Income | $16.5M | 98% |
| Noninterest Income | $284.0K | 2% |
